Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma (clinicaltrials.gov) - Sep 10, 2026 - P1 | N=56 | Recruiting | Sponsor: Cerenome | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2027 ➔ Mar 2028 | Trial primary completion date: Mar 2027 ➔ Mar 2028
Enrollment open • Trial completion date • Trial primary completion date • Brain Cancer • Ependymoma • Glioma • High Grade Glioma • Oligodendroglioma • Oncology • Pediatrics • Solid Tumor
|